United States - English - NLM (National Library of Medicine)

boiron - canis lupus familiaris milk (unii: g39p120jqt) (canis lupus familiaris milk - unii:g39p120jqt) - breast discomfort associated with pms* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

boiron - canis lupus familiaris milk (unii: g39p120jqt) (canis lupus familiaris milk - unii:g39p120jqt) - breast discomfort associated with pms* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

boiron - canis lupus familiaris milk (unii: g39p120jqt) (canis lupus familiaris milk - unii:g39p120jqt) - breast discomfort associated with pms* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

India - English - Central Drugs Standard Control Organization

biosciences - methyl prednisolone - tab - 4mg - 100

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

chinese patent medicines & medicated liquors centre (penang) sdn. bhd. - mel; periostracum cicadae; semen persicae; scolopendra subspinipes; salviae miltiorrhizae radix; rhizoma coptidis; radix scrophulariae; radix rehmanniae; radix paeoniae rubra; radix et rhizoma rhei; radix angelicae sinensis extract; herba taraxaci/taraxacum mongolicum; herba taraxaci/taraxacum mongolicum; glycyrrhiza glabra radix/liquorice root; fructus forsythiae; fritillaria thunbergii (bulbus); flos lonicerae; cathamus tinctorius(safflower) oil -

Malta - English - Medicines Authority

antibiotice s.a. 1 valea lupului street, 707410, iasi, romania - nebivolol - tablet - nebivolol 5 mg - beta blocking agents

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - furosemide, quantity: 500 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; silicon dioxide; maltodextrin - indications as at 01 jan 1991 : frusemide in a high-dosage formulation such as urex forte ( 500 mg tablets ) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l / day dialysis has to be used.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; mannitol; sodium hydroxide - frusemide high dosage formulations are intended exclusively for patients with severely impaired renal function. use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function, e.g. in chronic glomerular nephritis, lupus erythematosus and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l/day, dialysis has to be used.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - azathioprine, quantity: 50 mg - injection, powder for - excipient ingredients: sodium hydroxide - indications as at 11 february 2005: imuran is used as an immunosuppressant antimetabolite either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. imuran, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. imuran, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering form the following: severe rheumatoid arthritis; systemic lupus erythematosus; dermatomyositis/polymyositis; autoimmune chronic active hepatitis; pemphigus vulgaris; polya